Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DWP-450 · 1 trial · 1 indication
The primary safety analysis was the calculation of the proportion of subjects with at least one adverse event that occurred from Day 0 through Day 365.
| Arm | Type | Description |
|---|---|---|
| Botulinum toxin, Tyoe A | EXPERIMENTAL | DWP-450 (Botulinum toxin, Type A) |
| Name | Type | Description |
|---|---|---|
| DWP-450 (Botulinum purified neurotoxin, Type A) | BIOLOGICAL | Botulinum toxin, Type A |
Inclusion Criteria: * Subjects must be an adult 18 years of age and over * Subject is able to provide informed consent and comply with study instructions * Subject has moderate-to-severe glabellar lines on maximum frown as assessed by the investigator and subject using the GLS * Subject is willing ...
DWP-450 is being developed for the treatment of glabellar frown lines, the vertical lines that form between the eyebrows. It is a botulinum toxin type A product candidate studied in a Phase 2 safety trial in adults aged 18 years and older in the United States.
DWP-450 targets botulinum toxin type A, a toxin-based agent. Botulinum toxin type A products act on the nerve endings that signal muscle contraction, which is the basis for their use in smoothing dynamic facial lines such as glabellar frown lines.
DWP-450 is being developed by Evolus, Inc., which trades on the Nasdaq under the ticker EOLS. Evolus is a biopharmaceutical company focused on aesthetic and dermatology products, and DWP-450 is one of its botulinum toxin type A development programs.
DWP-450 is in Phase 2 development. Its clinical program consists of one completed Phase 2 trial, and no trials are currently active. The candidate remains investigational and has not been approved by the FDA for any indication.
DWP-450 has been studied in the Phase 2 trial NCT02428608, titled Safety Study of DWP-450 (Botulinum Toxin, Type A) to Treat Glabellar Lines, also known as EV-006. The trial enrolled 570 participants in the United States and is completed.
Yes. DWP-450 is also known as DWP-450 (Botulinum purified neurotoxin, Type A). The two names refer to the same Evolus development candidate, a botulinum toxin type A product being studied for glabellar frown lines.